ABCL AbCellera Biologics
- 3.850
- +0.070+1.85%
AbCellera Biologics News
AbCellera Partners With PE Firms to Develop Antibody Drugs, Company Creation
Express News | Abcellera:Under Terms, Abcellera Will Participate as Equity Founding Partner With Potential for Milestones, Royalties on Future Sales of Each Product
Express News | Abcellera Biologics Inc: Under Terms of Collaboration, Viking and ArrowMark Will Be Majority Shareholders of Newcos
Express News | Abcellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
Institutional Owners May Consider Drastic Measures as AbCellera Biologics Inc.'s (NASDAQ:ABCL) Recent US$91m Drop Adds to Long-term Losses
Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain fo
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
AbCellera (NASDAQ:ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024,
Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
Over the last year, a good number of insiders have significantly increased their holdings in AbCellera Biologics Inc. (NASDAQ:ABCL). This is encouraging because it indicates that insiders are more opt
Peter Thiel Resigns From AbCellera Board for Personal Reasons
AbCellera Announces Resignation of Board Member
AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to
Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
AbCellera to Present at Upcoming Investor Conferences in March
AbCellera (NASDAQ:ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m.
Obesity Drugs to Expand U.S. GDP by 1% in the Coming Years: Goldman Sachs
AbCellera Biologics Stock Upgraded to Buy on Q4 Results, R&D Progress
AbCellera Biologics Raised to Buy From Hold by Benchmark
AbCellera Biologics Raised to Buy From Hold by Benchmark
AbCellera Biologics: A Strong Buy on Robust Pipeline and Solid Financial Outlook
Express News | AbCellera Biologics Shares Are Trading Lower After the Company Reported Mixed Q4 Financial Results
Analysis
Price Target
No Data
